Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 5/20 | 0.46 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.46 |
| ▸ | PSEN1 | P49768 | 9/20 | 0.44 |
| ▸ | PSEN2 | P49810 | 9/20 | 0.44 |
| ▸ | APH1B | Q8WW43 | 9/20 | 0.44 |
| ▸ | NCSTN | Q92542 | 9/20 | 0.44 |
| ▸ | APH1A | Q96BI3 | 9/20 | 0.44 |
| ▸ | PSENEN | Q9NZ42 | 9/20 | 0.44 |
| ▸ | GLP1R | P43220 | 6/20 | 0.42 |
| ▸ | GCGR | P47871 | 1/20 | 0.42 |
| ▸ | GIPR | P48546 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL38651798 | 1.00 | OPRM1 (0.46) | OPRM1OPRD1OPRK1PSEN1PSEN2 | |
| SCHEMBL38651875 | 1.00 | OPRM1 (0.46) | OPRM1OPRD1OPRK1PSEN1PSEN2 | |
| SCHEMBL30543477 | 0.98 | OPRM1 (0.44) | OPRM1OPRD1OPRK1PSEN1PSEN2 | |
| SCHEMBL30543483 | 0.98 | OPRM1 (0.45) | OPRM1OPRD1OPRK1PSEN1PSEN2 | |
| SCHEMBL30543487 | 0.98 | OPRM1 (0.45) | OPRM1OPRD1OPRK1PSEN1PSEN2 | |
| SCHEMBL30543484 | 0.98 | OPRM1 (0.44) | OPRM1OPRD1OPRK1PSEN1PSEN2 | |
| SCHEMBL30892071 | 0.96 | OPRM1 (0.44) | OPRM1OPRD1OPRK1PSEN1PSEN2 | |
| SCHEMBL30852879 | 0.96 | OPRM1 (0.44) | OPRM1OPRD1OPRK1PSEN1PSEN2 | |
| SCHEMBL30887322 | 0.95 | GLP1R (0.44) | OPRM1OPRD1OPRK1PSEN1PSEN2 | |
| SCHEMBL30543485 | 0.94 | OPRM1 (0.43) | OPRM1OPRD1OPRK1PSEN1PSEN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119350471-A | Tenipout peptide synthesis method | 中肽生化有限公司 | 2025-01-24 | — | — | CN | claimed |
| CN-119219745-A | Preparation of tel method of poisein | 深圳翰宇药业股份有限公司 | 2024-12-31 | — | — | CN | claimed |
| WO-2025130972-A1 | SYNTHETIC METHOD FOR TIRZEPATIDE | 深圳翰宇药业股份有限公司 | 2025-06-26 | — | — | WO | disclosed |
| CN-119350471-B | Tenipout peptide synthesis method | 中肽生化有限公司 | 2025-04-25 | — | — | CN | disclosed |
| CN-119350471-A | Tenipout peptide synthesis method | 中肽生化有限公司 | 2025-01-24 | — | — | CN | disclosed |
| US-20250019410-A1 | PROCESS FOR THE PREPARATION OF TIRZEPATIDE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2025-01-16 | — | — | US | disclosed |
| CN-119219745-A | Preparation of tel method of poisein | 深圳翰宇药业股份有限公司 | 2024-12-31 | — | — | CN | disclosed |
| CN-117106055-A | Synthesis method of telipopeptide | 杭州思诺达医药科技有限责任公司 | 2023-11-24 | — | — | CN | disclosed |
| US-20230241178-A1 | LONG ACTING GLP-1/GIP DUAL AGONISTS | SUN PHARMACEUTICAL IND LTD (IN) | 2023-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230241178-A1 | LONG ACTING GLP-1/GIP DUAL AGONISTS | GLP1R, GIPR, GPR119 | OPRM1 1258/4885OPRD1 923/4885OPRK1 861/4885 |
| US-20250019410-A1 | PROCESS FOR THE PREPARATION OF TIRZEPATIDE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | SYK, TREH, QDPR | OPRM1 4271/4885OPRD1 1919/4885OPRK1 3125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.